LYS Share Price Performance
€0
0.00 (0.00%)
Price €0
Share Pricen/a
Lysogene S.A. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
LYS Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
Lysogene S.A. Key Details
Last Reported Earnings
Jun 30, 2022
Next Reporting Earnings
n/a
- -0.42
- 100.00%
- -57.76%
- -402.9%
About LYS
- Founded
- 2009
- Employees
- 22
- CEO
- WebsiteView website
Lysogene S.A., a biopharmaceutical gene therapy company, focuses on the discovery and development of therapies for children with neurodegenerative lysosomal storage disorders. Its clinical programs include LYS-SAF302, which is in Phase II/III clinical trial for the treatment of mucopolysaccharidosis type IIIA; and LYS-GM101 that is in Phase I/II trial for the treatment of GM1 gangliosidosis. The company has a research collaboration with the Yeda Research and Development Co Ltd. for developing a novel AAV gene therapy approach for neuronopathic gaucher disease, parkinson disease, and other diseases. Lysogene S.A. was founded in 2009 and is based in Neuilly-sur-Seine, France.
